They also suggest the use of GLP-1 RA or SGLT-2i for individuals with T2DM with or at high risk for ASCVD, and/or CKD in the Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2022 [15]. The gene discussed is GLP1R; the disease is chronic kidney disease.